Download PDF
Dialyse aktuell 2018; 22(07): 302-310
DOI: 10.1055/a-0668-5039
Schwerpunkt | Transplantation
© Georg Thieme Verlag KG Stuttgart · New York

Wann sollte man die Immunsuppression nach Ende der Nierentransplantatfunktion absetzen?

Eine allgemeingültige Empfehlung gibt es nicht
Markus Tölle
Medizinische Klinik mit Schwerpunkt Nephrologie, Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In den nächsten Jahren wird bei vielen Patienten über eine zweite, dritte oder auch vierte Nierentransplantation nachgedacht werden, da die initialen Transplantate nach längerer oder kürzerer Funktion nicht mehr ausreichend entgiften und damit erneut eine maschinelle Nierenersatztherapie notwendig ist. Auch wenn das transplantierte Organ nicht mehr ausreichend funktionstüchtig ist, bleibt es ein Fremdkörper, kann weiterhin vom Körper als ‚fremd‘ erkannt und damit auch abgestoßen werden. Dies wiederum kann massive Komplikationen für betroffene Patienten nach sich ziehen. Auf der anderen Seite ist eine Immunsuppression durchaus mit kardiovaskulären, infektiologischen, aber auch mit malignen Risiken für den Patienten unter einer maschinellen Nierenersatztherapie verbunden. Damit stellt sich dem behandelnden Arzt bei einem versagenden Transplantat immer die Frage, wie mittelfristig mit der verwendeten immunsuppressiven Behandlung umgegangen werden sollte.

 

  • Literatur

  • 1 Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462 doi: 10.1111/j.1600–6143.2010.03283.x
    CrossrefPubMedGoogle Scholar
  • 2 Cecka JM. The UNOS Renal Transplant Registry. Clin Transpl 2002; 1-20
    PubMedGoogle Scholar
  • 3 Knoll G, Muirhead N, Trpeski L. et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5: 1719-1724 doi: 10.1111/j.1600–6143.2005.00921.x
    CrossrefPubMedGoogle Scholar
  • 4 Gill JS, Abichandani R, Kausz AT. et al. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002; 62: 1875-1883 doi: 10.1046/j.1523–1755.2002.00640.x
    CrossrefPubMedGoogle Scholar
  • 5 Rao PS, Schaubel DE, Jia X. et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007; 49: 294-300 doi: 10.1053/j.ajkd.2006.11.022
    CrossrefPubMedGoogle Scholar
  • 6 Gill JS, Rose C, Pereira BJ. et al. The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients. Kidney Int 2007; 71: 442-447 doi: 10.1038/sj.ki.5002072
    CrossrefPubMedGoogle Scholar
  • 7 Meier-Kriesche HU, Kaplan B. Death after graft loss: a novel endpoint for renal transplantation. Transplant Proc 2001; 33: 3405-3406
    CrossrefPubMedGoogle Scholar
  • 8 McCaughan JA, Patterson CC, Maxwell AP. et al. Factors influencing survival after kidney transplant failure. Transplant Res 2014; 3: 18 doi: 10.1186/2047–1440–3-18
    CrossrefPubMedGoogle Scholar
  • 9 Pham PT, Pham PC. Immunosuppressive management of dialysis patients with recently failed transplants. Semin Dial 2011; 24: 307-313 doi: 10.1111/j.1525–139X.2011.00864.x
    CrossrefPubMedGoogle Scholar
  • 10 Bayliss GP, Gohh RY, Morrissey PE. et al. Immunosuppression after renal allograft failure: a survey of US practices. Clin Transplant 2013; 27: 895-900 doi: 10.1111/ctr.12254
    CrossrefPubMedGoogle Scholar
  • 11 Kassakian CT, Ajmal S, Gohh RY. et al. Immunosuppression in the failing and failed transplant kidney: optimizing outcomes. Nephrol Dial Transplant 2016; 31: 1261-1269 doi: 10.1093/ndt/gfv256
    CrossrefPubMedGoogle Scholar
  • 12 Casey MJ, Wen X, Kayler LK. et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. Transplantation 2014; 98: 306-311 doi: 10.1097/TP.0000000000000057
    PubMedGoogle Scholar
  • 13 Jassal SV, Lok CE, Walele A. et al. Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. Am J Kidney Dis 2002; 40: 178-183 doi: 10.1053/ajkd.2002.33927
    CrossrefPubMedGoogle Scholar
  • 14 Smak Gregoor PJ, Zietse R, van Saase JL. et al. Immunosuppression should be stopped in patients with renal allograft failure. Clin Transplant 2001; 15: 397-401
    CrossrefPubMedGoogle Scholar
  • 15 Woodside KJ, Schirm ZW, Noon KA. et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97: 648-653 doi: 10.1097/01.TP.0000437558
    PubMedGoogle Scholar
  • 16 Gregoor PJ, Kramer P, Weimar W van Saase JL. Infections after renal allograft failure in patients with or without low-dose maintenance immunosuppression. Transplantation 1997; 63: 1528-1530
    CrossrefPubMedGoogle Scholar
  • 17 Perl J, Zhang J, Gillespie B. et al. Reduced survival and quality of life following return to dialysis after transplant failure: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2012; 27: 4464-4472 doi: 10.1093/ndt/gfs386
    CrossrefPubMedGoogle Scholar
  • 18 Vajdic CM, van Leeuwen MT, Webster AC. et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18: 2297-2303 doi: 10.1158/1055–9965.EPI-09–0278
    CrossrefPubMedGoogle Scholar
  • 19 Stewart JH, Vajdic CM, van Leeuwen MT. et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009; 24: 3225-3231 doi: 10.1093/ndt/gfp331
    CrossrefPubMedGoogle Scholar
  • 20 Dantal J, Hourmant M, Cantarovich D. et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628 doi: 10.1016/S0140–6736(97)08496–1
    CrossrefPubMedGoogle Scholar
  • 21 Gallagher MP, Kelly PJ, Jardine M. et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21: 852-858 doi: 10.1681/ASN.2009101043
    CrossrefPubMedGoogle Scholar
  • 22 van Leeuwen MT, Webster AC, McCredie MR. et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010; 340: c570 doi: 10.1136/bmj.c570
    CrossrefPubMedGoogle Scholar
  • 23 Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther Adv Endocrinol Metab 2016; 7: 110-127 doi: 10.1177/2042018816641580
    CrossrefPubMedGoogle Scholar
  • 24 Zsom L, Wagner L, Fulop T. Minimization vs tailoring: where do we stand with personalized immunosuppression during renal transplantation in 2015?. World J Transplant 2015; 5: 73-80 doi: 10.5500/wjt.v5.i3.73
    PubMedGoogle Scholar
  • 25 Noel C, Hazzan M, Boukelmoune M. et al. Indication for allograft nephrectomy after irreversible rejection: is there an ideal delay?. Transplant Proc 1997; 29: 145-146 doi: 10.1016/S0041–1345(96)00041–3
    CrossrefPubMedGoogle Scholar
  • 26 Freier DT, Haines RF, Rosenzweig J. et al. Sequential renal transplants: some surgical and immunological implications on management of the first homograft. Surgery 1976; 79: 262-267
    PubMedGoogle Scholar
  • 27 DiSesa VJ, Tilney NL. Conservative management of the failed renal allograft: indications for transplant nephrectomy. Curr Surg 1982; 39: 417-418
    PubMedGoogle Scholar
  • 28 Thomas PP, Jacob CK, Kirubakaran MG. et al. Indication for routine allograft nephrectomy in cases of irreversible rejection. Transplantation 1989; 48: 155
    PubMedGoogle Scholar
  • 29 Matzinger P. Graft tolerance: a duel of two signals. Nat Med 1999; 5: 616-617 doi: 10.1038/9458
    CrossrefPubMedGoogle Scholar
  • 30 Askandarani S, Aloudah N, Al Enazi H. et al. Late renal allograft rupture associated with cessation of immunosuppression following graft failure. Case Rep Transplant 2011; 2011: 512893 doi: 10.1155/2011/512893
    PubMedGoogle Scholar
  • 31 Vanrenterghem Y, Khamis S. The management of the failed renal allograft. Nephrol Dial Transplant 1996; 11: 955-957 doi: 10.1093/ndt/11.6.955
    CrossrefPubMedGoogle Scholar
  • 32 Roberts CS, LaFond J, Fitts CT. et al. New patterns of transplant nephrectomy in the cyclosporine era. J Am Coll Surg 1994; 178: 59-64
    PubMedGoogle Scholar
  • 33 O’Sullivan DC, Murphy DM, McLean P. et al. Transplant nephrectomy over 20 years: factors involved in associated morbidity and mortality. J Urol 1994; 151: 855-858 doi: 10.1016/S0022–5347(17)35105–4
    CrossrefPubMedGoogle Scholar
  • 34 Johnston O, Rose C, Landsberg D. et al. Nephrectomy after transplant failure: current practice and outcomes. Am J Transplant 2007; 7: 1961-1967 doi: 10.1111/j.1600–6143.2007.01884.x
    CrossrefPubMedGoogle Scholar
  • 35 Lopez-Gomez JM, Perez-Flores I, Jofre R. et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15: 2494-2501 doi. 10.1097/01.ASN.0000137879.97445.6E
    CrossrefPubMedGoogle Scholar
  • 36 Ayus JC, Achinger SG. At the peril of dialysis patients: ignoring the failed transplant. Semin Dial 2005; 18: 180-184 doi: 10.1111/j.1525–139X.2005.18304.x
    CrossrefPubMedGoogle Scholar
  • 37 Ayus JC, Achinger SG, Lee S. et al. Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol 2010; 21: 374-380 doi: 10.1681/ASN.2009050480
    CrossrefPubMedGoogle Scholar
  • 38 Rodger RS, Watson MJ, Sellars L. et al. Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis. Q J Med 1986; 61: 1039-1046 doi: 10.1093/oxfordjournals.qjmed.a068059
    Google Scholar
  • 39 Verresen L, Vanrenterghem Y, Waer M. et al. Corticosteroid withdrawal syndrome in dialysis patients. Nephrol Dial Transplant 1988; 3: 476-477 doi: 10.1093/oxfordjournals.ndt.a091703
    CrossrefPubMedGoogle Scholar
  • 40 Shapiro R, Carroll PB, Tzakis AG. et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49: 1011-1013
    CrossrefPubMedGoogle Scholar
  • 41 Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
    PubMedGoogle Scholar
  • 42 Shemin D, Bostom AG, Laliberty P. et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85-90 doi: 10.1053/ajkd.2001.25198
    CrossrefPubMedGoogle Scholar
  • 43 Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis. Nephron 1997; 77: 13-28 doi: 10.1159/000190242
    CrossrefPubMedGoogle Scholar
  • 44 Perl J, Dong J, Rose C. et al. Is dialysis modality a factor in the survival of patients initiating dialysis after kidney transplant failure?. Perit Dial Int 2013; 33: 618-628 doi: 10.3747/pdi.2012.00280
    CrossrefPubMedGoogle Scholar
  • 45 Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-1732 doi: 10.1038/sj.ki.5000382
    CrossrefPubMedGoogle Scholar
  • 46 Pham PT, Everly M, Faravardeh A. et al. Management of patients with a failed kidney transplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy. World J Nephrol 2015; 4: 148-159 doi: 10.5527/wjn.v4.i2.148; doi: 10.5527/wjn.v4.i2.148
    PubMedGoogle Scholar
  • 47 Wong G, Chua S, Chadban SJ. et al. Waiting time between failure of first graft and second kidney transplant and graft and patient survival. Transplantation 2016; 100: 1767-1775 doi: 10.1097/TP.0000000000000953
    CrossrefPubMedGoogle Scholar
  • 48 Augustine JJ, Woodside KJ, Padiyar A. et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94: 738-743 doi: 10.1097/TP.0b013e3182612921
    PubMedGoogle Scholar
  • 49 Singh P, Filippone EJ, Colombe BW. et al. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized. Clin Transplant 2016; 30: 71-80 doi: 10.1111/ctr.12663
    CrossrefPubMedGoogle Scholar
  • 50 Rao SBR PS, Pastan S, Gebel H. et al. Gradual vs rapid withdrawal of immunosuppression after kidney allograft failure results in less allosensitization, decreased rate of de-novo donor specific antibody and reduced need for allograft nephrectomy. Am J Transplant 2013; 13 [abstract]
    Google Scholar
  • 51 Sumrani N, Delaney V, Hong JH. et al. The influence of nephrectomy of the primary allograft on retransplant graft outcome in the cyclosporine era. Transplantation 1992; 53: 52-55
    CrossrefPubMedGoogle Scholar
  • 52 Khakhar AK, Shahinian VB, House AA. et al. The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome. Transplant Proc 2003; 35: 862-863 doi: 10.1016/S0041–1345(02)04031–9
    CrossrefPubMedGoogle Scholar
  • 53 Douzdjian V, Rice JC, Carson RW. et al. Renal retransplants: effect of primary allograft nephrectomy on early function, acute rejection and outcome. Clin Transplant 1996; 10: 203-208
    PubMedGoogle Scholar
  • 54 Del Bello A, Congy-Jolivet N, Sallusto F. et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7: 1310-1319 doi: 10.2215/CJN.00260112
    CrossrefPubMedGoogle Scholar
  • 55 Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257: 1130-1134 doi: 10.2215/CJN.00260112
    CrossrefPubMedGoogle Scholar
  • 56 Nishinaka H, Nakafusa Y, Hirano T. et al. Graft persistence effectively induces and maintains donor-specific unresponsiveness. J Surg Research 1997; 68: 145-152 doi: 10.1006/jsre.1997.5053
    CrossrefPubMedGoogle Scholar
  • 57 Jackson A, McSherry C, Butters K. et al. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity. Hum Immunol 1997; 55: 148-153 doi: 10.1016/S0198–8859(97)0098–0
    CrossrefPubMedGoogle Scholar
  • 58 Scornik JC, Kriesche HU. Human leukocyte antigen sensitization after transplant loss: timing of antibody detection and implications for prevention. Hum Immunol 2011; 72: 398-401 doi: 10.1016/j.humimm.2011.02.018
    CrossrefPubMedGoogle Scholar
  • 59 Del Bello A, Congy N, Sallusto F. et al. Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation 2012; 93: 936-941 doi: 10.1097/TP.0b013e31824b3720
    CrossrefPubMedGoogle Scholar
  • 60 Kendrick EA, Davis CL. Managing the failing allograft. Semin Dial 2005; 18: 529-539 doi: 10.1111/j.1525–139X.2005.00100.x
    CrossrefPubMedGoogle Scholar
  • 61 Bennett WM. The failed renal transplant: in or out?. Semin Dial 2005; 188-189 doi: 10.1111/j.1525–139X.2005.00100.x
    PubMedGoogle Scholar
  • 62 Andrews PA. Summary of the British Transplantation Society Guidelines for management of the failing kidney transplant. Transplantation 2014; 98: 1130-1133 doi: 10.1097/TP.0000000000000426
    CrossrefPubMedGoogle Scholar